Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0015-6264(72)80148-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite.
Int J Pharm
May 2022
Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.
Since late 2019, concerns regarding trace levels of the probable human carcinogen N-dimethylnitrosamine (NDMA) in Metformin-containing pharmaceuticals have been an issue if they exceeded the maximum allowable intake of 96 ng/day for a medicine with long-term intake. Here, we report results from an extensive analysis of NDMA content along the active pharmaceutical ingredient (API) manufacturing process as well as two different drug product manufacturing processes. Our findings confirm that Metformin API is not a significant source of NDMA found in Metformin pharmaceuticals and that NDMA is created at those steps of the drug product manufacturing that introduce heat and nitrite.
View Article and Find Full Text PDFNDMA analytics in metformin products: Comparison of methods and pitfalls.
Eur J Pharm Sci
January 2022
Merck KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany. Electronic address:
Background: For nearly three years, the concerns regarding trace levels of N-nitrosamines in pharmaceuticals and the associated cancer risk have significantly expanded and are a major issue facing the global pharmaceutical industry. N-nitrosodimethylamine (NDMA) found in formulations of the popular anti-diabetic drug metformin is a prominent example. This has resulted in product recalls raising the profile within the media.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!